AZD5991

Overview

AZD5991 is an Mcl-1 inhibitor being tested in multiple myeloma.

SparkCures ID 292
Developed By AstraZeneca
Generic Name AZD5991
Treatment Classifications
  • Myeloid Cell Leukemia-1 (MCL-1) Inhibitor

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.